Northern Trust Corp Acquires 108,038 Shares of Certara, Inc. (NASDAQ:CERT)

Northern Trust Corp grew its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 14.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 877,010 shares of the company's stock after acquiring an additional 108,038 shares during the quarter. Northern Trust Corp owned about 0.54% of Certara worth $9,340,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Venturi Wealth Management LLC raised its holdings in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Certara during the 4th quarter worth $47,000. Blue Trust Inc. lifted its position in shares of Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after buying an additional 822 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its position in shares of Certara by 204.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after buying an additional 3,656 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Trading Down 0.8%

Shares of CERT traded down $0.09 during mid-day trading on Tuesday, reaching $11.69. 1,379,364 shares of the company were exchanged, compared to its average volume of 1,314,796. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.76. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a market capitalization of $1.90 billion, a PE ratio of -58.45, a PEG ratio of 9.29 and a beta of 1.57. The business has a 50 day simple moving average of $11.73 and a two-hundred day simple moving average of $11.75.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. During the same period last year, the company earned $0.10 earnings per share. The firm's revenue was up 9.7% compared to the same quarter last year. On average, analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the subject of several recent analyst reports. Stephens restated an "overweight" rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. KeyCorp increased their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Finally, Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Certara currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.